Appreciable success has been recorded in each area of our policy shift. To ensure achievement of set operational objectives arising from our new policy and to ensure desired business growth occasional operational restructuring becomes inevitable. Currently the business is structured into the following four operational units for greater focus, better result orientation and higher profit growth.
This business group is responsible for the marketing and sales of Neimeth branded products including our flagship home grown product CIKLAVIT for the management of sickle cell disease. The group has responsibility for all newly developed products as well as our branded generics and Alliance products.
It currently has 15 major product groups divided into 39 presentations in its portfolio. Expectedly, this group is the fastest growing group of the businesses both in sales volume and product portfolio. It has high volume products like NCP, Pyrantrin, Obron – 6, Homtamin G and Pancemol.
Neimeth is now poised to re-enter the lucrative Nigerian Animal Health business, which has very robust volume and profit potentials. We expect to regain a controlling market share in a few years. We have introduced our own brand of poultry and large animal range of anthelmintics, as well as production enhancing medicaments. We will also enter into strategic alliances in key disease areas that show great business potentials.
Neimeth is firmly on ground in the Anglophone West African Countries of Ghana, Sierra Leone, Liberia and the Gambia. Our key products like Ciklavit, Homtamin G; NCP, Antimal and Normoretic have been registered there and are in rising demand. Entry into the Francophone Countries has commenced with product registration formalities. We have a field sales team on ground in Ghana, where demand for Ciklavit and NCP are tremendous.